公开(公告)号：US20240299417A1

公开(公告)日：2024-09-12

申请号：US18432829

申请日：2024-02-05

申请人： Northwestern University

发明人： Thomas A. MUSTOE ,  Robert D. Galiano ,  Seok Jong Hong ,  Ping Xie ,  Shengxian Jia

IPC分类号： A61K31/575 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K9/14 ,  A61K31/22 ,  A61K31/225 ,  A61K31/366 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/44 ,  A61P17/02

CPC分类号： A61K31/575 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K9/1075 ,  A61K9/14 ,  A61K31/22 ,  A61K31/225 ,  A61K31/366 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/44 ,  A61P17/02

摘要： Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.

公开(公告)号：US12083107B2

公开(公告)日：2024-09-10

申请号：US18049652

申请日：2022-10-26

申请人： Bjoern Colin Kahrs

发明人： Bjoern Colin Kahrs

IPC分类号： A61K31/05 ,  A61K9/00 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/216 ,  A61K31/225 ,  A61K31/26 ,  A61K31/385 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/47 ,  A61P1/04 ,  A61P5/48 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P21/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00

CPC分类号： A61K31/4439 ,  A61K9/0053 ,  A61K31/05 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/216 ,  A61K31/225 ,  A61K31/26 ,  A61K31/385 ,  A61K31/426 ,  A61K31/47 ,  Y02A50/30 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/12 ,  A61K2300/00 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/216 ,  A61K2300/00 ,  A61K31/26 ,  A61K2300/00 ,  A61K31/385 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/47 ,  A61K2300/00

摘要： The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

公开(公告)号：US20240252557A1

公开(公告)日：2024-08-01

申请号：US18424585

申请日：2024-01-26

申请人： Natals, Inc.

发明人： Nima ALAMDARI ,  Adeline M. GRIER-WELCH ,  Shilpa A. RAUT ,  Mastaneh SHARAFI ,  Katerina SCHNEIDER ,  Arianne Y. VANCE

IPC分类号： A61K35/747 ,  A61K9/48 ,  A61K31/225 ,  A61K35/745 ,  A61K35/76 ,  A61K47/44 ,  A61P1/00

CPC分类号： A61K35/747 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4891 ,  A61K31/225 ,  A61K35/745 ,  A61K35/76 ,  A61K47/44 ,  A61P1/00

摘要： Described herein are multi-biotic supplements containing a mixture of postbiotics, prebiotics, and probiotics within nested capsules, for use in supporting the health of a subject, including gut health, digestive health, and immune health.

公开(公告)号：US12036206B2

公开(公告)日：2024-07-16

申请号：US17352674

申请日：2021-06-21

申请人： William H. Cross, III

发明人： William H. Cross, III

IPC分类号： A61K31/385 ,  A61K31/185 ,  A61K31/197 ,  A61K31/198 ,  A61K31/225

CPC分类号： A61K31/385 ,  A61K31/185 ,  A61K31/197 ,  A61K31/198 ,  A61K31/225 ,  A61K31/185 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/225 ,  A61K2300/00 ,  A61K31/385 ,  A61K2300/00

摘要： The invention provides pharmaceutical compositions having improved effects and synergistic efficacy against pain, and provides methods for their use to treat pain, wherein the composition comprises: a sulfur-containing amino acid; a carnitine compound; and at least one compound that is a L-citrulline compound or a beta-alanine compound.

公开(公告)号：US20240207227A1

公开(公告)日：2024-06-27

申请号：US18364880

申请日：2023-08-03

申请人： Novartis AG

发明人： Fabian Chen ,  Surya Prakash Ayalasomayajula ,  Christopher Bush ,  Masha Berkhin ,  Gesine Winzenburg ,  Bernd Trueby

IPC分类号： A61K31/41 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K31/216 ,  A61K31/225 ,  A61K45/06 ,  A61P9/00

CPC分类号： A61K31/41 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/216 ,  A61K31/225 ,  A61K45/06 ,  A61P9/00

摘要： The present invention relates to methods and pharmaceutical compositions for treating heart failure in a pediatric human patient comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril and valsartan in a pharmaceutically acceptable form and in a 1:1 molar ratio.

公开(公告)号：US11974994B2

公开(公告)日：2024-05-07

申请号：US17358883

申请日：2021-06-25

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Tomoko Kirihara ,  Atsushi Shimazaki ,  Masatsugu Nakamura

IPC分类号： A61K31/444 ,  A61K31/225 ,  A61K31/4178 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/542 ,  A61K31/551 ,  A61K31/5575 ,  A61K45/06 ,  C07D401/14

CPC分类号： A61K31/444 ,  A61K31/225 ,  A61K31/4178 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/542 ,  A61K31/551 ,  A61K31/5575 ,  A61K45/06 ,  C07D401/14 ,  A61K31/444 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00 ,  A61K31/5575 ,  A61K2300/00 ,  A61K31/498 ,  A61K2300/00 ,  A61K31/542 ,  A61K2300/00

摘要： A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.

公开(公告)号：US20240108571A1

公开(公告)日：2024-04-04

申请号：US18528684

申请日：2023-12-04

申请人： Slayback Pharma LLC.

发明人： Ashish Anilrao Dubewar ,  Amit Anil Charkha ,  Sumitra Ashokkumar Pillai ,  Pradeep Kumar Kare ,  Kumar Swamy Ummiti ,  Shanker Mamidi ,  Mayur Anshiram Adhav

IPC分类号： A61K9/00 ,  A61K31/221 ,  A61K31/225 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18

CPC分类号： A61K9/0019 ,  A61K31/221 ,  A61K31/225 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183

摘要： The present invention relates to injectable pharmaceutical compositions comprising therapeutically effective amount of succinylcholine chloride, one or more pharmaceutically acceptable aqueous solvents, and one or more stabilizing agents selected from aliphatic polyols; lower alkyl alcohols; amino acids having at least one additional amino, carboxyl or hydroxyl group; amino alcohols; and aliphatic dicarboxylic acids having at least one hydroxyl or amino group, or α-β unsaturation. The compositions are stable at room temperature for at least 30 days. Methods of manufacturing the injectable pharmaceutical compositions are also provided. The composition may be provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe, and are suitable for subcutaneous, intravenous or intramuscular administration as an adjunct to general anesthesia, to facilitate tracheal intubation, and/or to provide skeletal muscle relaxation during surgery or mechanical ventilation.

公开(公告)号：US11944625B2

公开(公告)日：2024-04-02

申请号：US17175079

申请日：2021-02-12

申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION ,  DANA-FARBER CANCER INSTITUTE, INC.

发明人： James Bradner ,  Jun Qi ,  Dennis Buckley ,  Leonard I. Zon ,  Elizabeth Macari

IPC分类号： A61K31/517 ,  A61K31/225 ,  A61K31/403 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/7048 ,  A61K45/06 ,  A61P7/06

CPC分类号： A61K31/517 ,  A61K31/225 ,  A61K31/403 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/7048 ,  A61P7/06 ,  A61K45/06

摘要： The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.

公开(公告)号：US20240009101A1

公开(公告)日：2024-01-11

申请号：US18474052

申请日：2023-09-25

申请人： JUPITER WELLNESS, INC.

发明人： Ofer A. Goren ,  John McCoy

IPC分类号： A61K8/49 ,  A61P17/14 ,  A61K8/33 ,  A61K8/35 ,  A61K8/37 ,  A61K8/84 ,  A61K8/96 ,  A61K9/00 ,  A61K9/08 ,  A61K9/16 ,  A61K9/51 ,  A61K31/11 ,  A61K31/122 ,  A61K31/225 ,  A61K31/353 ,  A61K31/506 ,  A61M5/142 ,  A61Q7/00 ,  A61Q7/02

CPC分类号： A61K8/4953 ,  A61P17/14 ,  A61K8/33 ,  A61K8/35 ,  A61K8/355 ,  A61K8/37 ,  A61K8/498 ,  A61K8/84 ,  A61K8/96 ,  A61K9/0014 ,  A61K9/08 ,  A61K9/1647 ,  A61K9/5115 ,  A61K31/11 ,  A61K31/122 ,  A61K31/225 ,  A61K31/353 ,  A61K31/506 ,  A61M5/14276 ,  A61Q7/00 ,  A61Q7/02 ,  A61K2800/5922 ,  A61K2800/78 ,  A61K2800/87

摘要： Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

公开(公告)号：US20230181669A1

公开(公告)日：2023-06-15

申请号：US17990156

申请日：2022-11-18

申请人： Amy Grosso-Piacentino

发明人： Amy Grosso-Piacentino

IPC分类号： A61K36/899 ,  A61K31/045 ,  A61K31/122 ,  A61K31/22 ,  A61K31/225 ,  A61K31/343 ,  A61K31/513 ,  A61K36/534 ,  A61K36/54 ,  A61K36/61 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20 ,  A61K31/125

CPC分类号： A61K36/899 ,  A61K31/045 ,  A61K31/122 ,  A61K31/22 ,  A61K31/225 ,  A61K31/343 ,  A61K31/513 ,  A61K36/534 ,  A61K36/54 ,  A61K36/61 ,  A61K45/06 ,  A61K9/0014 ,  A61K9/2072 ,  A61K31/125

摘要： A skin-sensitizing formulation is provided in an edible, softgel pill. A person engaged in a sexual activity bites down on the pill, thereby effectuating the oral release of the skin-sensitizing formulation. This allows the skin-sensitizing formulation to be spread to a sexual partner, on any part of the skin or sexual region of the body preferably through oral contact with the partner. The skin-sensitizing substance is spread to the partner directly on the skin or through oral contact or beneath a condom worn by the partner. The skin-sensitizing formulation may include an essential mint oil, analog or derivative, and may further includes an enhancer, rubefacient, counterirritant, anesthetic, k-opioid receptor activator, or TRPM8 activator. Various inactive ingredients are also disclosed.